2026 MaTOS GU | Session VIII | Prostate Cancer
Overview
Dr. Pinski: mHSPC treatment evolved from ADT to triplet therapy (ADT+RPI+docetaxel), improving survival; biomarkers guide personalized care.
Dr. Slovin: PARP inhibitors improve PFS in mHSPC, especially with BRCA1/2; key trials positive, but risks like MDS highlight need for biomarkers.
Dr. Iravani: lutetium PSMA improves PFS (OS in VISION); outcomes depend on PSMA expression; imaging + biomarkers key for patient selection.
Dr. Choudhury: AKT inhibitors show PFS benefit in PTEN-loss prostate cancer, but no OS gain; efficacy tied to PTEN status, with notable toxicities.
Dr. Petrylak: ARV-110/766 PROTACs target AR mutations in mCRPC; show PSA responses, with ARV-766 and lutetium combo promising in trials.
Roundtable Discussion: prostate cancer remains complex; need better patient selection, biomarkers, and tailored therapy; PSMA imaging and de-escalation under study.
Dr. Slovin: PARP inhibitors improve PFS in mHSPC, especially with BRCA1/2; key trials positive, but risks like MDS highlight need for biomarkers.
Dr. Iravani: lutetium PSMA improves PFS (OS in VISION); outcomes depend on PSMA expression; imaging + biomarkers key for patient selection.
Dr. Choudhury: AKT inhibitors show PFS benefit in PTEN-loss prostate cancer, but no OS gain; efficacy tied to PTEN status, with notable toxicities.
Dr. Petrylak: ARV-110/766 PROTACs target AR mutations in mCRPC; show PSA responses, with ARV-766 and lutetium combo promising in trials.
Roundtable Discussion: prostate cancer remains complex; need better patient selection, biomarkers, and tailored therapy; PSMA imaging and de-escalation under study.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Atish D. Choudhury, MD, PhD
Daniel P. Petrylak, MD
Jacek K. Pinski, MD, PhD
Susan Slovin, MD, PhD
Amir Iravani, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
